Itaconix（ITXX.F）株式概要Itaconix plcは、その子会社とともに、北米とヨーロッパでホームケアおよびパーソナルケア用途の植物由来ポリマーの開発に従事している。 詳細ITXX.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長1/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間19%増加すると予測されています リスク分析過去5年間で収益は年間6.3%減少しました。 株式の流動性は非常に低い 意味のある時価総額がありません ( $20M )すべてのリスクチェックを見るITXX.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.5542.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-14m25m2016201920222025202620282031Revenue US$25.1mEarnings US$2.3mAdvancedSet Fair ValueView all narrativesItaconix plc 競合他社Origin MaterialsSymbol: NasdaqCM:ORGNMarket cap: US$6.1mTantech HoldingsSymbol: NasdaqCM:TANHMarket cap: US$6.4mGreystone LogisticsSymbol: OTCPK:GLGIMarket cap: US$6.2mADM Tronics UnlimitedSymbol: OTCPK:ADMTMarket cap: US$4.6m価格と性能株価の高値、安値、推移の概要Itaconix過去の株価現在の株価UK£1.5552週高値UK£1.8552週安値UK£1.05ベータ1.011ヶ月の変化4.73%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化703.11%IPOからの変化13,990.91%最新ニュースお知らせ • May 29Itaconix Advances Development of Next Generation Plant-Based PaintsItaconix plc announced further progress in the development of a new class of paints enabled by Itaconix's line of BIOAsterix ingredients. The Company has filed a patent application covering paint formulations incorporating BIOAsterix ingredients and has also filed a trademark application relating to the new class of paints under development. As part of the next stage of development activities, Itaconix has signed an agreement with an established specialty paint company to support the completion and evaluation of initial paint products using BIO*Asterix ingredients. The programme forms part of the Company's broader strategy to expand the application of its plant-based polymer platform into new application categories, with a strong focus on product safety, performance, and sustainability.お知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom最新情報をもっと見るRecent updatesお知らせ • May 29Itaconix Advances Development of Next Generation Plant-Based PaintsItaconix plc announced further progress in the development of a new class of paints enabled by Itaconix's line of BIOAsterix ingredients. The Company has filed a patent application covering paint formulations incorporating BIOAsterix ingredients and has also filed a trademark application relating to the new class of paints under development. As part of the next stage of development activities, Itaconix has signed an agreement with an established specialty paint company to support the completion and evaluation of initial paint products using BIO*Asterix ingredients. The programme forms part of the Company's broader strategy to expand the application of its plant-based polymer platform into new application categories, with a strong focus on product safety, performance, and sustainability.お知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025お知らせ • Oct 16Itaconix plc Announces Launch of the Itaconix SPARX ProgramItaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry.お知らせ • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024お知らせ • Jul 16Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024.お知らせ • Apr 30Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and CleanersItaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates.お知らせ • Apr 17Itaconix plc Provides Revenue Guidance for the Year 2024Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations.お知らせ • Apr 16Itaconix plc, Annual General Meeting, May 20, 2024Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United Kingdomお知らせ • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024お知らせ • Feb 09Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive DirectorItaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets.お知らせ • Dec 07Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations.お知らせ • Sep 05Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023お知らせ • May 25+ 1 more updateItaconix plc, Annual General Meeting, Jun 28, 2023Itaconix plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London London United Kingdomお知らせ • Feb 03+ 1 more updateItaconix plc, Annual General Meeting, Feb 22, 2023Itaconix plc, Annual General Meeting, Feb 22, 2023, at 11:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane :London United Kingdom Agenda: To allot Ordinary Shares and to grant rights to subscribe for or to convert any security into Ordinary Shares up to an aggregate nominal amount of £8,203,187.39; to grant the Directors authority to allot equity securities under the authority given by resolution 1 for cash free of the statutory pre-emption rights which would otherwise apply, such authority to be limited; to consider Directors be authorised in addition to any authority granted under resolution 2 to allot equity securities for cash free of statutory pre-emption rights.お知らせ • Jan 05Itaconix plc Announces Board ChangesItaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).株主還元ITXX.FUS ChemicalsUS 市場7D4.7%4.3%2.2%1Yn/a8.0%24.8%株主還元を見る業界別リターン: ITXX.FがUS Chemicals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: ITXX.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is ITXX.F's price volatile compared to industry and market?ITXX.F volatilityITXX.F Average Weekly Movementn/aChemicals Industry Average Movement6.9%Market Average Movement7.2%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.1%安定した株価: ITXX.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のITXX.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト200528John Shawitaconix.comItaconix plc は子会社とともに、北米とヨーロッパでホームケアおよびパーソナルケア用途の植物由来ポリマーの開発に従事している。Itaconix DSP 2K、Itaconix TSI 122、Itaconix TSI 322、Itaconix ONZ 100、Itaconix ONZ 105、Itaconix ONZ 400、Itaconix ONZ 075、Itaconix SF 505などのクリーニング製品、ベラフレッシュZP20、ベラフレッシュZP30、ベラフレッシュZP75、ベラフレッシュZP95、ベラフレッシュNE 100などの衛生・美容製品を提供している。同社は以前はRevolymer plcとして知られていたが、2017年2月にItaconix plcに社名を変更した。Itaconix plcは2005年に設立され、ニューハンプシャー州ストラスハムに本社を置いている。もっと見るItaconix plc 基礎のまとめItaconix の収益と売上を時価総額と比較するとどうか。ITXX.F 基礎統計学時価総額US$19.89m収益（TTM）-US$1.38m売上高(TTM)US$10.50m1.9xP/Sレシオ-14.4xPER（株価収益率ITXX.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ITXX.F 損益計算書（TTM）収益US$10.50m売上原価US$6.86m売上総利益US$3.64mその他の費用US$5.02m収益-US$1.38m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.10グロス・マージン34.69%純利益率-13.14%有利子負債／自己資本比率0%ITXX.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/15 09:53終値2026/06/15 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Itaconix plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Alexander BrooksCanaccord Genuity
お知らせ • May 29Itaconix Advances Development of Next Generation Plant-Based PaintsItaconix plc announced further progress in the development of a new class of paints enabled by Itaconix's line of BIOAsterix ingredients. The Company has filed a patent application covering paint formulations incorporating BIOAsterix ingredients and has also filed a trademark application relating to the new class of paints under development. As part of the next stage of development activities, Itaconix has signed an agreement with an established specialty paint company to support the completion and evaluation of initial paint products using BIO*Asterix ingredients. The programme forms part of the Company's broader strategy to expand the application of its plant-based polymer platform into new application categories, with a strong focus on product safety, performance, and sustainability.
お知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026
お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025
お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.
お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • May 29Itaconix Advances Development of Next Generation Plant-Based PaintsItaconix plc announced further progress in the development of a new class of paints enabled by Itaconix's line of BIOAsterix ingredients. The Company has filed a patent application covering paint formulations incorporating BIOAsterix ingredients and has also filed a trademark application relating to the new class of paints under development. As part of the next stage of development activities, Itaconix has signed an agreement with an established specialty paint company to support the completion and evaluation of initial paint products using BIO*Asterix ingredients. The programme forms part of the Company's broader strategy to expand the application of its plant-based polymer platform into new application categories, with a strong focus on product safety, performance, and sustainability.
お知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026
お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025
お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.
お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025
お知らせ • Oct 16Itaconix plc Announces Launch of the Itaconix SPARX ProgramItaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry.
お知らせ • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024
お知らせ • Jul 16Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024.
お知らせ • Apr 30Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and CleanersItaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates.
お知らせ • Apr 17Itaconix plc Provides Revenue Guidance for the Year 2024Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations.
お知らせ • Apr 16Itaconix plc, Annual General Meeting, May 20, 2024Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United Kingdom
お知らせ • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024
お知らせ • Feb 09Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive DirectorItaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets.
お知らせ • Dec 07Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations.
お知らせ • Sep 05Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023
お知らせ • May 25+ 1 more updateItaconix plc, Annual General Meeting, Jun 28, 2023Itaconix plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London London United Kingdom
お知らせ • Feb 03+ 1 more updateItaconix plc, Annual General Meeting, Feb 22, 2023Itaconix plc, Annual General Meeting, Feb 22, 2023, at 11:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane :London United Kingdom Agenda: To allot Ordinary Shares and to grant rights to subscribe for or to convert any security into Ordinary Shares up to an aggregate nominal amount of £8,203,187.39; to grant the Directors authority to allot equity securities under the authority given by resolution 1 for cash free of the statutory pre-emption rights which would otherwise apply, such authority to be limited; to consider Directors be authorised in addition to any authority granted under resolution 2 to allot equity securities for cash free of statutory pre-emption rights.
お知らせ • Jan 05Itaconix plc Announces Board ChangesItaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).
